Shanghai RAAS Blood Products Co Ltd
SZSE:002252

Watchlist Manager
Shanghai RAAS Blood Products Co Ltd Logo
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Watchlist
Price: 7.45 CNY -3.37% Market Closed
Market Cap: 98.5B CNY
Have any thoughts about
Shanghai RAAS Blood Products Co Ltd?
Write Note

Shanghai RAAS Blood Products Co Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai RAAS Blood Products Co Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Free Cash Flow
ÂĄ299m
CAGR 3-Years
-32%
CAGR 5-Years
-7%
CAGR 10-Years
7%
Beigene Ltd
HKEX:6160
Free Cash Flow
-ÂĄ11.9B
CAGR 3-Years
-24%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Free Cash Flow
ÂĄ1.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Free Cash Flow
ÂĄ378.2m
CAGR 3-Years
69%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Free Cash Flow
ÂĄ5.5B
CAGR 3-Years
-12%
CAGR 5-Years
86%
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Free Cash Flow
ÂĄ1.9B
CAGR 3-Years
69%
CAGR 5-Years
81%
CAGR 10-Years
N/A
No Stocks Found

Shanghai RAAS Blood Products Co Ltd
Glance View

Market Cap
98.5B CNY
Industry
Biotechnology

Shanghai RAAS Blood Products Co., Ltd. is a key player in China's biopharmaceutical landscape, specializing in the production and supply of human blood products and diagnostic reagents. Founded in 1992, the company has grown to become one of the largest blood product manufacturers in the country, serving the increasing demand for high-quality and safe blood-derived therapies. The company’s extensive portfolio includes a range of products such as human albumin, immunoglobulins, and coagulants, which are essential for treating various medical conditions, from trauma care to chronic diseases. With a strong commitment to innovation and quality, RAAS has established robust research and development capabilities, ensuring that it stays at the forefront of advancements in blood product technologies. For investors, Shanghai RAAS represents a compelling opportunity in the rapidly expanding Chinese healthcare market. The company operates in a highly regulated environment, giving it a competitive edge through rigorous quality control and adherence to international standards. Furthermore, as China’s aging population grows and healthcare spending increases, the demand for reliable blood products is expected to rise significantly. RAAS has strategically positioned itself to capture this market growth, supported by a diversified customer base that includes hospitals and medical institutions. With its commitment to sustainability, innovation, and shareholder value, investing in Shanghai RAAS not only aligns with a growing industry but also offers the potential for solid returns as the company continues to expand its footprint in both domestic and international markets.

Intrinsic Value
5.68 CNY
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Shanghai RAAS Blood Products Co Ltd's Free Cash Flow?
Free Cash Flow
299m CNY

Based on the financial report for Jun 30, 2024, Shanghai RAAS Blood Products Co Ltd's Free Cash Flow amounts to 299m CNY.

What is Shanghai RAAS Blood Products Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
7%

Over the last year, the Free Cash Flow growth was -86%. The average annual Free Cash Flow growth rates for Shanghai RAAS Blood Products Co Ltd have been -32% over the past three years , -7% over the past five years , and 7% over the past ten years .

Back to Top